<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:postCode>B-9000</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:postCode>B-9000</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/04829FFC-7F01-4150-91BF-69653656B424"><gtr:id>04829FFC-7F01-4150-91BF-69653656B424</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Adcock</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/977F0EC2-CBAD-4E2F-A4B8-68C5053E7C39"><gtr:id>977F0EC2-CBAD-4E2F-A4B8-68C5053E7C39</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Barnes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801266"><gtr:id>6E76B850-8F4E-46E5-8ED3-BAD7BF9CB196</gtr:id><gtr:title>Regulation of IL-13 transcription in human T-cells by GATA-3/NF-AT complexes: modulation by corticosteroids</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801266</gtr:grantReference><gtr:abstractText>Asthma affects 1 in 12 of the UK population, with 5.2 million people currently receiving treatment. The UK has one of the highest prevalence of asthma in young adults in Europe and the numbers of children reporting asthma symptoms has risen six fold over the last 30 years. Asthma costs the NHS #889m per year and it is estimated that at least 12.7 million working days are lost due to asthma each year. The rising prevalence of allergic diseases and accompanying health care costs are therefore major health and socio-economic problems. Most asthmatic subjects respond to treatment with inhaled corticosteroids although the mechanisms underlying their action are not clear. We wish to determine how corticosteroids reduce the expression of key proteins involved in asthma particularly the inflammatory mediator interleukin 13 (IL-13). Understanding how corticosteroids work in mild asthma may help to develop new drugs to target these processes that have fewer side-effects and may be able to treat patients with severe asthma who do not improve with corticosteroids. This will result in improved patient care with less side-effects and in cost savings to the NHS,</gtr:abstractText><gtr:technicalSummary>Asthma affects 1 in 12 of the UK population, with 5.2 million people currently receiving treatment. Asthma costs the NHS #889m per year and it is estimated that at least 12.7 million working days are lost due to asthma each year. Inflammation in allergic diseases, such as asthma, is mediated via expression of the cytokines interleukin (IL)-4, IL-5 and IL-13 from T helper-2 (Th2) cells. These Th2 cytokines are regulated predominantly by the transcription factor GATA-3, which is mainly expressed in Th2 cells and is also responsible for their differentiation. GATA-3 is a phospho-protein whose activity is regulated by p38 mitogen activated protein kinase (MAPK). 
Corticosteroids are highly effective in the treatment of allergic inflammation, with marked suppression of Th2 cytokines including IL-13 in asthmatic airways and in peripheral blood T-cells. In non-T-cells, corticosteroids mainly target nuclear factor kappaB (NF-?B); however, NF-?B does not control Th2 cytokine expression to any extent. We wish, therefore to examine how corticosteroids, acting through their receptor (GR), can suppress IL-13 release. We hypothesise that suppression of p38 MAPK activity and recruitment of HDAC2 to the GATA-3 complex plays a key role in GR-mediated repression of IL-13 transcription in human T-cells in vitro and in vivo. We propose that GR suppresses human IL-13 expression through pleitropic mechanisms including attenuation of GATA-3 phosphorylation and acetylation, competition for importins, prevention of NF-AT complex formation and induction of T-bet expression. We will examine this effect in human T-cells in vitro and ex vivo and also in vivo following exposure of mild asthmatic patients to inhaled corticosteroids.
These studies will provide mechanisms and pathways by which corticosteroids control IL-13 expression in human T-cells and may highlight p38 MAPK as a potential treatment for controlling Th2 cytokine expression in asthma.</gtr:technicalSummary><gtr:fund><gtr:end>2012-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>357830</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghent</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>IUAP AIReWAY II</gtr:description><gtr:id>E2473A2A-9090-4056-9881-64F44648F9D2</gtr:id><gtr:impact>none to date - just started</gtr:impact><gtr:outcomeId>BiHscF626hY-1</gtr:outcomeId><gtr:partnerContribution>Large range of in vitro and in vivo models to look at interaction of bacterial and viral infection on allergen challenge and cigarette smoke models</gtr:partnerContribution><gtr:piContribution>Investigation of the effect of airway infections on animal models and in vitro human primary cell models of asthma and COPD. We will be looking at effects of viral infection of human epithelial cells using SILAC approaches and on innate immune cells in an ozone model of COPD after infection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>UBIOPRED</gtr:description><gtr:id>3BE26CB0-F01A-4663-8D60-29FB603EBC5C</gtr:id><gtr:impact>Patient collection and initial handprint analysis performed. Beginning to measure human handprints with murine and cell model handprints.

PubMed PMID: 22630041.
PubMed PMID: 21106547.</gtr:impact><gtr:outcomeId>i85AmUwS8n2-1</gtr:outcomeId><gtr:partnerContribution>Other Workpackages cover the following: Patient cohort collection, SOPs, definition of patient groups, Management, ethics, publication, bronchoscopy, 'omics analysis and systems analysis.</gtr:partnerContribution><gtr:piContribution>I run WP6 which aims to get improved murine models of severe asthma and examines steroid responses in cells from severe asthma</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Centre</gtr:description><gtr:id>9F9545F5-DE1B-4925-B995-F3ED844FD00F</gtr:id><gtr:impact>Other than contribution to Centre no grant/papers as yet. Expected 2011.
Joint PhD student.</gtr:impact><gtr:outcomeId>MSTcVZvMNZ5-1</gtr:outcomeId><gtr:partnerContribution>Enhanced my ability to examine chromatin changes in human T-cells by collaboration with Dr Lavender and Cousins. Access to deep sequencing capacity through MRC Centre and BRC.</gtr:partnerContribution><gtr:piContribution>Greater understanding of T-cell regulation in severe asthma. Further understandign of steroid responses in severe asthma.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>UBIOPRED patient interaction</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>62F2A501-3035-4142-A795-565D80DDE8E0</gtr:id><gtr:impact>Annual UBIOPRED Meeting invites representatives of asthma patient groups from across EU. We work with them to discuss priorities for future work and patient involvement
I discussed work with Asthma UK regarding research into how steroids work in asthma and why understanding differences in severe asthma are important

Altered clinical trial to use different group of patients</gtr:impact><gtr:outcomeId>pmXkmu6mQCN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imperial Festival 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CE81F953-1745-4980-AE44-9E1E74F87305</gtr:id><gtr:impact>Described in the following website:
http://www3.imperial.ac.uk/festival/previousfestivals/imperialfestival2012

Increased public awareness about lung disease, particularly COPD. Engagement of children with a locally devised COPD board game.</gtr:impact><gtr:outcomeId>5461f0e1eaa292.99521812</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www3.imperial.ac.uk/festival/previousfestivals/imperialfestival2012</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient and volunteer engagement</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>37694003-5D0D-4C16-BB18-C4F67A484A11</gtr:id><gtr:impact>2 Open Days that invited all patients and normal control subjects to present our research and to get feedback and answer questions from study participants. Very positive feedback from the meeting and more are planned.</gtr:impact><gtr:outcomeId>58b6e931825f42.68230427</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Heart &amp; Lung Shop</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AD164E60-382F-4104-8995-A952922B7E07</gtr:id><gtr:impact>Details provided on the following website:
http://www1.imperial.ac.uk/nhli/public_engagement/the_curious_act/heart_and_lung_repair_shops/



High level of interest from the public in participating in clinical trials and in receiving more information. We plan to continue these popular events in the future.</gtr:impact><gtr:outcomeId>5461efcaa84a56.57210001</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www1.imperial.ac.uk/nhli/public_engagement/the_curious_act/heart_and_lung_repair_shops/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory Placement for final year school pupils</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>17A9AC37-F02C-4A7C-A491-037404C4AF03</gtr:id><gtr:impact>2 week placement visit to different laboratories and hospital laboratories.</gtr:impact><gtr:outcomeId>56c464392d8970.28691178</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bring Your Child to Work Day at NHLI</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C5968C5F-DB3A-4321-A531-28E2AB873C28</gtr:id><gtr:impact>Described in the following website:

http://www1.imperial.ac.uk/nhli/aboutus/child_to_work_day/ - 


Great interest in the children. Encouraged discussion of life-work balance between colleagues with children.
Interest to run similar programmes in local schools.</gtr:impact><gtr:outcomeId>5461f1f78a7851.68526768</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www1.imperial.ac.uk/nhli/aboutus/child_to_work_day/</gtr:url><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hakathon for developing new devices for respiratory diseases</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0ECD05F5-2508-4965-93F9-F18939686008</gtr:id><gtr:impact>Interactive meeting at Imperial College and beamed to MIT (Cambridge, USA) to discuss new monitoring devices for patients with lung diseases such as COPD. Involved discussion about patients needs with engineers scientists and doctors. Received a lot of national publicity.</gtr:impact><gtr:outcomeId>56c4637bb959d8.38641102</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/eventssummary/event_7-9-2015-17-28-1</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imperial College Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BE357260-BE17-4DFE-A641-B04019D06F08</gtr:id><gtr:impact>Excellent feedback over 2 days regarding impact of asthma and COPD on everyday life of people

arranged visit to school</gtr:impact><gtr:outcomeId>nrLNsorVbKH</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>00DCF203-9989-4EC7-B396-5888FE7F3AB5</gtr:id><gtr:outcomeId>TGbToJnmWjx0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B2891461-783A-4B63-8AE4-0AB1D331DFB9</gtr:id><gtr:outcomeId>LKUqZy6HUwn0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of ERS/ATS Task Force on severe asthma</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>3C94D4B8-2907-4021-A7FD-7F28126A35C7</gtr:id><gtr:outcomeId>cB1Y4fWKcTo</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8D1D9DA2-80AB-45E8-8073-AF118A999179</gtr:id><gtr:title>Epigenetics of asthma.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/379bfdd93ec9595ae27bc2fa44a1da66"><gtr:id>379bfdd93ec9595ae27bc2fa44a1da66</gtr:id><gtr:otherNames>Durham AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>Lv2XpLHXxFP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80983FBE-C9D4-4E1A-9D03-01CF2DDF39CB</gtr:id><gtr:title>Overcoming steroid unresponsiveness in airways disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee684f9047e0bd9660d2d01912b5dee3"><gtr:id>ee684f9047e0bd9660d2d01912b5dee3</gtr:id><gtr:otherNames>Adcock IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>faDbpFqXoTC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4456453C-87AA-43EE-85C5-FB20E48CC2ED</gtr:id><gtr:title>Coordinated regulation of IL-4 and IL-13 expression in human T cells: 3C analysis for DNA looping.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6097a4853ca60dfe018be6e438b6967"><gtr:id>f6097a4853ca60dfe018be6e438b6967</gtr:id><gtr:otherNames>Yao X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>pm_16567_27_22226971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>744DBCD9-9328-433E-9071-DFF1248C9D3B</gtr:id><gtr:title>Nuclear factor ?-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2edc291b131fcdabbdabef1cd8e5c8a0"><gtr:id>2edc291b131fcdabbdabef1cd8e5c8a0</gtr:id><gtr:otherNames>Price LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e162e162b4383b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E80E5C0A-AA7B-4063-9020-1B88AA36B074</gtr:id><gtr:title>Decreased percentage of CD4(+)Foxp3(+)TGF-?(+) and increased percentage of CD4(+)IL-17(+) cells in bronchoalveolar lavage of asthmatics.</gtr:title><gtr:parentPublicationTitle>Journal of inflammation (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b62d1153bbda0e19c1d4ca943f5f371c"><gtr:id>b62d1153bbda0e19c1d4ca943f5f371c</gtr:id><gtr:otherNames>Barczyk A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1476-9255</gtr:issn><gtr:outcomeId>54631a39cb0e73.26761531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CF6348F-A961-415B-A02A-5EEC2E33E3A5</gtr:id><gtr:title>Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389c257b57485646aed29b91fe7e757b"><gtr:id>389c257b57485646aed29b91fe7e757b</gtr:id><gtr:otherNames>Shao D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>54631a39578aa5.79176723</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFEDA83B-BC09-483B-B14A-0C075984389C</gtr:id><gtr:title>Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9449fa9ef8b160778003df358aed892f"><gtr:id>9449fa9ef8b160778003df358aed892f</gtr:id><gtr:otherNames>Maneechotesuwan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>efJXHPaPw7x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>128D5373-5E2B-4E5D-B9AB-4FC9D403A427</gtr:id><gtr:title>Klotho expression is reduced in COPD airway epithelial cells: effects on inflammation and oxidant injury.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22cce05d0597c82a50ce7fe461c5d8a4"><gtr:id>22cce05d0597c82a50ce7fe461c5d8a4</gtr:id><gtr:otherNames>Gao W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>585d58269eba55.20042572</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>794B8992-340E-479A-BEAF-B1D77708A4BC</gtr:id><gtr:title>Bronchial epithelial cells: The key effector cells in the pathogenesis of chronic obstructive pulmonary disease?</gtr:title><gtr:parentPublicationTitle>Respirology (Carlton, Vic.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22cce05d0597c82a50ce7fe461c5d8a4"><gtr:id>22cce05d0597c82a50ce7fe461c5d8a4</gtr:id><gtr:otherNames>Gao W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1323-7799</gtr:issn><gtr:outcomeId>5675e24c41d2a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C69BD45D-3662-4B6C-AA39-378C994F4E34</gtr:id><gtr:title>Chromosome 17q21 SNP and severe asthma.</gtr:title><gtr:parentPublicationTitle>Journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8dbb8d576044b20a5ca4e13409ea1646"><gtr:id>8dbb8d576044b20a5ca4e13409ea1646</gtr:id><gtr:otherNames>Binia A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1434-5161</gtr:issn><gtr:outcomeId>dcQA2oA7a8h</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E361E2B-C223-410B-AE09-70CC21E37EFB</gtr:id><gtr:title>Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches.</gtr:title><gtr:parentPublicationTitle>Drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5190029ab216c357cc962e19a2158604"><gtr:id>5190029ab216c357cc962e19a2158604</gtr:id><gtr:otherNames>Marwick JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-6667</gtr:issn><gtr:outcomeId>mz3BuYRTJjv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C45BC54B-C3B9-4945-96CE-01956CBE39F5</gtr:id><gtr:title>BET proteins are a key component of immunoglobulin gene expression.</gtr:title><gtr:parentPublicationTitle>Epigenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9040e75d5f2567f87722ea524b7da40b"><gtr:id>9040e75d5f2567f87722ea524b7da40b</gtr:id><gtr:otherNames>Shim JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1750-192X</gtr:issn><gtr:outcomeId>5a31e053039e55.94707925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B11DE374-F45B-4478-A433-2DD6E2606278</gtr:id><gtr:title>An integrative systems biology approach to understanding pulmonary diseases.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/750c0140a7b00ab87f5a87557d058a37"><gtr:id>750c0140a7b00ab87f5a87557d058a37</gtr:id><gtr:otherNames>Auffray C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>Dohh5Fth1nV</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801266</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>